A Phase 1 interventional study of MK-6194 and MK-6194-matching placebo in Ulcerative Colitis, sponsored by Merck Sharp & Dohme LLC. Completed at 17 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Colitis, Ulcerative by Merck & Co., Inc — 2 open to participants now, 3 under way, 2 of them phase 3. Colitis, Ulcerative · Merck & Co., Inc.
Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 8th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 13 studies in Colitis, Ulcerative by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Canada, Chile and 9 more countries
Ages 18–75
Merck Sharp & Dohme LLC · Sites in United States, Czechia, France and 4 more countries
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 100 across the 11 interventional studies, 1,120 across the 2 observational. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Colitis, Ulcerative by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07463183Merck Sharp & Dohme LLCA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Colitis, Ulcerative by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants at risk for colorectal cancer must have a colonoscopy prior to or at screening as follows:
Exclusion Criteria:
Has severe colitis as evidenced by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received low dose of MK-6194 at specified less frequent intervals
Drug: MK-6194
Participants received medium dose of MK-6194 at specified more frequent intervals
Drug: MK-6194
Participants received high dose of MK-6194 at specified more frequent intervals
Drug: MK-6194
Participants received high dose MK-6194 at specified less frequent intervals
Drug: MK-6194
Participants received MK- 6194-matching placebo via subcutaneous injection, administered either at interval 1 or interval 2
Drug: MK-6194-matching placebo
Subcutaneous injection
Also known as: PT101
Subcutaneous injection
Number of Participants Who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 85 days
Number of Participants Who Interrupted or Discontinued Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to thestudy intervention
Time frame: Up to approximately 72 days
Maximum Concentration (Cmax) of MK-6194
Blood samples were collected at pre-specified time points to determine each participant's maximum concentration (Cmax). A participant's Cmax was defined as the maximum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the maximum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmax were calculated for each dosing group.
Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85.
Time to Cmax (Tmax) of MK-6194
Blood samples were collected at pre-specified time points to determine maximum concentration (Cmax) of MK-6194 in each participant's serum and corresponding time of maximum concentration (Tmax). A participant's Tmax was defined as the time post-dose that the maximum concentration of MK-6194 was observed in serum. The median and range of Tmax were calculated for each dosing group.
Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Minimum Concentration (Cmin) of MK-6194
Blood samples were collected at pre-specified time points to determine the minimum concentration (Cmin) of MK-6194 present in each participant's serum. A participant's Cmin was defined as the minimum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the minimum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmin were calculated for each dosing group.
Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Apparent Half-life (t1/2) of MK-6194
Blood samples were collected at pre-specified time points to determine the apparent half-life (t1/2) of MK-6194. Noncompartmental analysis was used to calculate t1/2 for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of t1/2 were calculated for each dosing group.
Time frame: Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85
Apparent Clearance (CL/F) of MK-6194
Blood samples were collected at pre-specified time points to determine the apparent clearance (CL/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate CL/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of CL/F were calculated for each dosing group.
Time frame: Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85
Apparent Volume of Distribution (Vd/F) of MK-6194
Blood samples were collected at pre-specified time points to determine the apparent volume of distribution (Vd/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate Vd/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of Vd/F were calculated for each dosing group.
Time frame: Final day of dosing at 12, 24-48 hours, and 120 hours (as available) post-dose; from the last day of dosing once each week up to approximately day 85
Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)
Blood samples were collected at pre-specified timepoints to determine the AUC0-t of MK-6194. AUC0-t is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to the last quantifiable concentration. Noncompartmental analysis was used to calculate AUC0-t for each participant. Geometric mean and geometric coefficient of variation of AUC0-t were calculated for each dosing group.
Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194
Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-6194. AUC0-inf is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to time=infinity. Noncompartmental analysis was used to calculate AUC0-inf for each participant; the portion of the AUC following the last observed concentration was assumed to follow an exponential elimination. Geometric mean and geometric coefficient of variation of AUC0-inf were calculated for each dosing group.
Time frame: Predose on all days of dosing; 12, 24-48, and 120 hours (as available) post dose on the first and last day of dosing; and once each week up to approximately day 85
Change in Number of Peripheral Regulatory T-cells (Tregs) in Whole Blood
Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The absolute change in the number of peripheral Tregs in whole blood was assessed.
Time frame: Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Change in Number of Natural Killer (NK) Cells in Whole Blood
Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of NK cells in whole blood is presented.
Time frame: Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Change in Number of Conventional T Cells (Tcons) in Whole Blood
Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of Tcons in whole blood is presented.
Time frame: Pre-dose (baseline) and weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Titer of Anti-drug Antibody (ADA) to MK-6194
Blood samples were collected for the determination of ADA to MK-6194 using a screening assay, ADA titer using a confirmatory assay, and neutralizing antibody to MK-6194 in participants with confirmed positive titers
Time frame: Pre dose (week 0) and Weeks 4, 8, 12
Upon concluding the Initial Blinded Treatment (IBT) phase, participants could either complete the study or enter one of the next 2 phases. Participants who achieved clinical response could enter the continued blinded treatment (CBT) phase and continue receiving the same treatment as the IBT phase. Participants who did not achieve clinical response could enter an open label (OL) phase and receive MK-6194 at the same dose/regimen of their IBT cohort for active MK-6194 treatment.
| Milestone | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Started | 7 | 11 | 18 | 10 | 11 |
| Continued in cbt phase | 2 | 1 | 2 | 3 | 3 |
| Treated in cbt phase | 2 | 1 | 2 | 3 | 3 |
| Continued in ol phase | 2 | 3 | 4 | 0 | 2 |
| Treated in ol phase | 3 | 4 | 4 | 0 | 0 |
| Completed | 7 | 9 | 16 | 10 | 9 |
| Not completed | 0 | 2 | 2 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 | 0 | 2 |
Blood samples were collected at pre-specified time points to determine each participant's maximum concentration (Cmax). A participant's Cmax was defined as the maximum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the maximum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmax were calculated for each dosing group.
| ng/mL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of MK-6194 | 9.55 ± 67.80 | 30.02 ± 95.85 | 51.80 ± 71.97 | 52.78 ± 178.96 | — |
Blood samples were collected at pre-specified time points to determine maximum concentration (Cmax) of MK-6194 in each participant's serum and corresponding time of maximum concentration (Tmax). A participant's Tmax was defined as the time post-dose that the maximum concentration of MK-6194 was observed in serum. The median and range of Tmax were calculated for each dosing group.
| hours | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Time to Cmax (Tmax) of MK-6194 | 12.00 (11.10 to 24.00) | 12.00 (11.50 to 24.50) | 12.05 (11.10 to 25.00) | 12.10 (11.20 to 12.20) | — |
Blood samples were collected at pre-specified time points to determine the minimum concentration (Cmin) of MK-6194 present in each participant's serum. A participant's Cmin was defined as the minimum concentration of MK-6194 observed in serum over the entire course of the study for that individual and was calculated by taking the minimum over all observed MK-6194 serum concentrations. Geometric mean and geometric coefficient of variation of Cmin were calculated for each dosing group.
| ng/mL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Minimum Concentration (Cmin) of MK-6194 | 0.08 ± 0.00 | 0.08 ± 0.00 | 0.09 ± 97.70 | 0.08 ± 0.00 | — |
Blood samples were collected at pre-specified time points to determine the apparent half-life (t1/2) of MK-6194. Noncompartmental analysis was used to calculate t1/2 for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of t1/2 were calculated for each dosing group.
| hours | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Apparent Half-life (t1/2) of MK-6194 | 193.28 ± 66.51 | 52.84 ± 23.89 | 42.06 ± 80.41 | 96.09 ± 16.51 | — |
Blood samples were collected at pre-specified time points to determine the apparent clearance (CL/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate CL/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of CL/F were calculated for each dosing group.
| L/hours | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of MK-6194 | 0.00 ± 66.28 | 0.01 ± 82.72 | 0.01 ± 95.07 | 0.01 ± 78.70 | — |
Blood samples were collected at pre-specified time points to determine the apparent volume of distribution (Vd/F) of MK-6194 observed in serum. Noncompartmental analysis was used to calculate Vd/F for each participant using the terminal elimination phase after the final dose. Geometric mean and geometric coefficient of variation of Vd/F were calculated for each dosing group.
| Liters | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) of MK-6194 | 1.61 ± 121.12 | 0.82 ± 96.99 | 0.55 ± 226.96 | 0.81 ± 93.17 | — |
Blood samples were collected at pre-specified timepoints to determine the AUC0-t of MK-6194. AUC0-t is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to the last quantifiable concentration. Noncompartmental analysis was used to calculate AUC0-t for each participant. Geometric mean and geometric coefficient of variation of AUC0-t were calculated for each dosing group.
| ng*hour/mL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) | 955.51 ± 39.92 | 2080.46 ± 55.64 | 3546.54 ± 67.17 | 3203.50 ± 117.92 | — |
Blood samples were collected at pre-specified timepoints to determine the AUC0-inf of MK-6194. AUC0-inf is defined as the area under the concentration-time curve from time=0 (Day 1 predose) to time=infinity. Noncompartmental analysis was used to calculate AUC0-inf for each participant; the portion of the AUC following the last observed concentration was assumed to follow an exponential elimination. Geometric mean and geometric coefficient of variation of AUC0-inf were calculated for each dosing group.
| ng*hour/mL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194 | 899.08 ± 36.53 | 2036.51 ± 71.46 | 3437.33 ± 65.59 | 3169.11 ± 120.37 | — |
Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The absolute change in the number of peripheral Tregs in whole blood was assessed.
| Cells/uL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Week 1 | 16.6 ± 46.10 | 24.0 ± 130.34 | 36.5 ± 76.68 | 31.0 ± 48.95 | 0.0 ± 107.20 |
| Week 2 | 15.2 ± 45.43 | 8.4 ± 78.56 | 0.0 ± 84.52 | 29.8 ± 100.53 | 6.0 ± 109.31 |
| Week 3 | 12.2 ± 113.83 | 24.5 ± 95.40 | 31.7 ± 92.24 | 15.2 ± 77.36 | 4.4 ± 96.26 |
| Week 4 | 5.1 ± 71.20 | 9.5 ± 78.31 | 12.8 ± 82.29 | 4.8 ± 115.02 | 0.0 ± 120.87 |
| Week 5 | 33.9 ± 61.55 | 0.0 ± 66.63 | 20.9 ± 78.63 | 35.5 ± 65.56 | 0.0 ± 92.71 |
| Week 6 | 9.0 ± 32.73 | 12.9 ± 73.27 | 9.8 ± 100.16 | 18.9 ± 58.45 | 0.0 ± 61.81 |
| Week 7 | 4.0 ± 53.29 | 32.3 ± 44.51 | 27.1 ± 69.98 | 7.4 ± 130.11 | 0.0 ± 66.82 |
| Week 8 | 3.9 ± 25.00 | 9.4 ± 101.40 | 8.8 ± 62.20 | 7.7 ± 101.49 | 0.0 ± 102.85 |
| Week 9 | 6.0 ± 121.24 | 21.1 ± 76.45 | 22.3 ± 83.28 | 42.1 ± 63.99 | 4.3 ± 101.64 |
| Week 10 | 2.3 ± 24.74 | 15.4 ± 55.42 | 11.3 ± 76.11 | 16.3 ± 91.23 | 3.5 ± 146.88 |
| Week 11 | — | 17.8 ± 79.90 | 24.6 ± 82.30 | — | 3.5 ± 117.48 |
| Week 12 | 5.9 ± 16.67 | 12.1 ± 56.51 | 6.4 ± 89.54 | 0.0 ± 77.22 | 4.7 ± 91.20 |
Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of NK cells in whole blood is presented.
| Cells/uL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Week 1 | 109.3 ± 117.56 | 0.0 ± 149.43 | 43.2 ± 86.39 | 110.0 ± 61.90 | 34.40 ± 60.38 |
| Week 2 | 124.7 ± 83.32 | 76.1 ± 62.77 | 48.6 ± 81.20 | 108.5 ± 55.48 | 19.2 ± 160.68 |
| Week 3 | 479.5 ± 85.51 | 50.3 ± 73.79 | 44.2 ± 110.61 | 68.4 ± 62.20 | 64.1 ± 87.37 |
| Week 4 | 292.2 ± 48.38 | 52.8 ± 67.48 | 0.0 ± 102.83 | 78.9 ± 73.40 | 42.1 ± 131.09 |
| Week 5 | 281.5 ± 27.43 | 42.1 ± 76.34 | 53.8 ± 61.16 | 133.2 ± 87.96 | 65.0 ± 129.61 |
| Week 6 | 169.0 ± 88.11 | 59.3 ± 72.56 | 54.7 ± 80.71 | 140.3 ± 78.10 | 55.3 ± 124.75 |
| Week 7 | 224.8 ± 83.09 | 0.0 ± 112.85 | 73.2 ± 66.16 | 82.0 ± 93.62 | 44.9 ± 119.10 |
| Week 8 | 272.9 ± 54.62 | 38.4 ± 113.46 | 43.7 ± 148.37 | 86.9 ± 49.10 | 30.4 ± 125.05 |
| Week 9 | 195.5 ± 4.35 | 92.8 ± 94.04 | 72.8 ± 74.20 | 94.0 ± 75.86 | 53.2 ± 81.75 |
| Week 10 | 159.6 ± 59.86 | 26.4 ± 83.25 | 46.0 ± 111.12 | 87.1 ± 99.38 | 84.5 ± 91.34 |
| Week 11 | — | 42.3 ± 94.19 | 47.0 ± 91.92 | — | 41.1 ± 163.74 |
| Week 12 | 70.6 ± 125.61 | 67.6 ± 60.56 | 58.4 ± 84.39 | 45.6 ± 119.58 | 40.9 ± 121.60 |
Blood samples were collected at pre-specified time points and analyzed by flow cytometry. The change in the number of Tcons in whole blood is presented.
| Cells/uL | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Week 1 | 216.9 ± 94.52 | 220.8 ± 94.37 | 91.2 ± 105.12 | 189.6 ± 66.58 | 57.6 ± 79.00 |
| Week 2 | 106.1 ± 124.15 | 100.8 ± 67.50 | 105.4 ± 121.23 | 184.1 ± 67.77 | 0.0 ± 71.58 |
| Week 3 | 347.3 ± 129.76 | 81.1 ± 98.95 | 123.7 ± 111.06 | 192.8 ± 60.55 | 127.7 ± 52.96 |
| Week 4 | 280.2 ± 116.12 | 122.4 ± 61.71 | 73.3 ± 108.47 | 163.4 ± 72.06 | 63.3 ± 105.58 |
| Week 5 | 456.3 ± 28.23 | 100.6 ± 74.36 | 126.2 ± 75.69 | 166.8 ± 76.19 | 79.3 ± 66.49 |
| Week 6 | 114.3 ± 119.18 | 57.9 ± 101.25 | 0.0 ± 101.48 | 193.9 ± 68.59 | 53.8 ± 90.84 |
| Week 7 | 137.7 ± 84.27 | 103.6 ± 68.22 | 68.6 ± 87.88 | 154.5 ± 70.64 | 66.1 ± 87.17 |
| Week 8 | 381.1 ± 34.64 | 109.0 ± 84.28 | 63.5 ± 82.18 | 159.1 ± 66.12 | 50.6 ± 93.80 |
| Week 9 | 250.3 ± 39.38 | 164.1 ± 51.01 | 128.8 ± 89.61 | 192.2 ± 71.43 | 141.5 ± 63.25 |
| Week 10 | 271.1 ± 81.50 | 33.4 ± 115.44 | 50.7 ± 98.06 | 147.3 ± 72.31 | 83.2 ± 92.61 |
| Week 11 | — | 76.1 ± 59.20 | 90.5 ± 80.69 | — | 102.0 ± 45.66 |
| Week 12 | 122.6 ± 134.20 | 73.2 ± 96.94 | 99.9 ± 77.32 | 153.3 ± 70.03 | 73.4 ± 82.45 |
Blood samples were collected for the determination of ADA to MK-6194 using a screening assay, ADA titer using a confirmatory assay, and neutralizing antibody to MK-6194 in participants with confirmed positive titers
| Titer | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Week 0 | — | 20.0 (20.0 to 20.0) | — | 20.0 (20.0 to 20.0) | — |
| Week 4 | — | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 160.0) | — |
| Week 8 | 160.0 (160.0 to 160.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 40.0) | — |
| Week 12 | 640.0 (640.0 to 640.0) | 40.0 (20.0 to 320.0) | 20.0 (20.0 to 640.0) | 40.0 (20.0 to 160.0) | — |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 7 | 10 | 18 | 10 | 7 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to thestudy intervention
| Participants | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo |
|---|---|---|---|---|---|
| Number of Participants Who Interrupted or Discontinued Study Treatment Due to an AE | 1 | 0 | 2 | 0 | 1 |
Collected over Up to approximately 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IBT: MK-6194 Low Dose Interval 1 (Less Frequent) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| IBT-MK-6194 Medium Dose- Interval 2 (More Frequent) | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| IBT: MK-6194 High Dose-Interval 2 (More Frequent) | 0/18 (0%) | 1/18 (5.6%) | 18/18 (100%) |
| IBT:MK-6194 High Dose-Interval 1 (Less Frequent) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| IBT: Placebo | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| CBT: MK-6194 Low Dose- Interval 1 (Less Frequent) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| CBT: MK-6194 Medium Dose- Interval 2 (More Frequent) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| CBT: MK-6194 High Dose- Interval 2 (More Frequent) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| CBT: MK-6194 High Dose - Interval 1 (Less Frequent) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| CBT: Placebo | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| OL: MK-6194 Low Dose -Interval 1 (Less Frequent) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| OL: MK-6194 Medium Dose- Interval 2 (More Frequent) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| OL: MK-6194 High Dose- Interval 2 (More Frequent) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | IBT: MK-6194 Low Dose Interval 1 (Less Frequent) | IBT-MK-6194 Medium Dose- Interval 2 (More Frequent) | IBT: MK-6194 High Dose-Interval 2 (More Frequent) | IBT:MK-6194 High Dose-Interval 1 (Less Frequent) | IBT: Placebo | CBT: MK-6194 Low Dose- Interval 1 (Less Frequent) | CBT: MK-6194 Medium Dose- Interval 2 (More Frequent) | CBT: MK-6194 High Dose- Interval 2 (More Frequent) | CBT: MK-6194 High Dose - Interval 1 (Less Frequent) | CBT: Placebo | OL: MK-6194 Low Dose -Interval 1 (Less Frequent) | OL: MK-6194 Medium Dose- Interval 2 (More Frequent) | OL: MK-6194 High Dose- Interval 2 (More Frequent) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/7 | 0/11 | 1/18 | 0/10 | 0/11 | 0/2 | 0/1 | 0/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Event | IBT: MK-6194 Low Dose Interval 1 (Less Frequent) | IBT-MK-6194 Medium Dose- Interval 2 (More Frequent) | IBT: MK-6194 High Dose-Interval 2 (More Frequent) | IBT:MK-6194 High Dose-Interval 1 (Less Frequent) | IBT: Placebo | CBT: MK-6194 Low Dose- Interval 1 (Less Frequent) | CBT: MK-6194 Medium Dose- Interval 2 (More Frequent) | CBT: MK-6194 High Dose- Interval 2 (More Frequent) | CBT: MK-6194 High Dose - Interval 1 (Less Frequent) | CBT: Placebo | OL: MK-6194 Low Dose -Interval 1 (Less Frequent) | OL: MK-6194 Medium Dose- Interval 2 (More Frequent) | OL: MK-6194 High Dose- Interval 2 (More Frequent) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EosinophiliaBlood and lymphatic system disorders | 3/7 | 7/11 | 17/18 | 4/10 | 2/11 | 1/2 | 1/1 | 1/2 | 1/3 | 1/3 | 0/3 | 3/4 | 1/4 |
| Injection site erythemaGeneral disorders | 5/7 | 7/11 | 12/18 | 5/10 | 0/11 | 2/2 | 1/1 | 2/2 | 1/3 | 0/3 | 1/3 | 2/4 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/7 | 0/11 | 0/18 | 1/10 | 0/11 | 1/2 | 0/1 | 0/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| VomitingGastrointestinal disorders | 0/7 | 0/11 | 0/18 | 0/10 | 0/11 | 1/2 | 0/1 | 0/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Injection site discolourationGeneral disorders | 0/7 | 0/11 | 0/18 | 0/10 | 0/11 | 1/2 | 0/1 | 0/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Injection site painGeneral disorders | 0/7 | 0/11 | 0/18 | 1/10 | 0/11 | 1/2 | 0/1 | 0/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Injection site pruritusGeneral disorders | 2/7 | 4/11 | 2/18 | 0/10 | 0/11 | 0/2 | 0/1 | 1/2 | 0/3 | 0/3 | 1/3 | 1/4 | 0/4 |
| Injection site swellingGeneral disorders | 0/7 | 0/11 | 0/18 | 1/10 | 0/11 | 1/2 | 0/1 | 0/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Blood bilirubin increasedInvestigations | 0/7 | 0/11 | 0/18 | 0/10 | 0/11 | 0/2 | 0/1 | 1/2 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Weight increasedInvestigations | 0/7 | 0/11 | 0/18 | 0/10 | 0/11 | 0/2 | 0/1 | 0/2 | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 |
| Age, Continuous(Years) | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 43.4 ± 11.59 | 43.4 ± 14.64 | 47.7 ± 11.43 | 43.3 ± 10.11 | 35.6 ± 11.85 | 43.2 ± 12.31 |
| Sex: Female, Male(Participants) | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 5 | 7 | 3 | 5 | 24 |
| Male | 3 | 6 | 11 | 7 | 6 | 33 |
| Ethnicity (NIH/OMB)(Participants) | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 0 | 3 | 5 |
| Not Hispanic or Latino | 5 | 11 | 18 | 9 | 8 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | MK-6194 Low Dose - Interval 1 (Less Frequent) | MK-6194 Medium Dose- Interval 2 (More Frequent) | MK-6194 High Dose - Interval 2 (More Frequent) | MK-6194 High Dose - Interval 1 (Less Frequent) | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 | 2 |
| White | 7 | 10 | 18 | 10 | 10 | 55 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Oct 2021 to primary completion in Jan 2024, 26 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 26 months is above that.
Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-6194